Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis

Khadije Maajani1, Mahmoud Khodadost2,3*, Arash Fattahi4, Ehsan Shahre stanaki1, Aliyar Pirouzi2, Fatemeh Khalili5, Hamed Fattahi6

Abstract

Background: Different studies have been conducted to estimate the survival rate of colorectal cancer in Iran but there is no overall estimate of the survival rate. The aim of this study was to calculate the pooled 1, 3, and 5-year survival rate of the patients with colorectal cancer in Iran. Methods: To retrieve relevant studies, we conducted a systematic search in Iranian databases, including Iran Medex, Magiran, SID, and international databases such as Medline/PubMed, Scopus, and Google scholar using “Colorectal Neoplasms” and “Survival Rate” as keywords up to December 1st, 2017. We used random effect model to estimate pooled 1, 3, and 5-year survival rates of the patients with colorectal cancer in Iran. To assess the heterogeneity, we used Chi-squared test at the 5% significance level (p <0.05) and I² Index. We used meta-regression and subgroup analysis to find a potential source of heterogeneity. Results: After a systematic search, 196 articles were found, of the 38 studies met the eligibility criteria and are included in our meta-analysis. The pooled 1, 3, and 5-year survival rates in patient with colorectal cancer were 0.84 (95% CI: 0.81-0.87), 0.64 (95%CI: 0.59-0.70), and 0.54 (95%CI: 0.49-0.58) respectively. The 5-year survival rate in the subgroup of women was 0.5 (0.44-0.56) and in male subgroup was 0.44 (0.40-0.48). In a subgroup of the tumor site, the 5-year survival rate in colon cancer was 0.6 (0.49-0.75) and rectum cancer was 0.54 (0.36-0.69). In multivariable models, there was a significant association between years of study and 5-year survival rate as a source of heterogeneity (β = 18.9, P=0.01). Conclusion: According to the results of this study, women had a better survival rate than men, and according to the tumor site, the 5-year survival rate in colon cancer was better than the rectum cancer. Keywords: Colorectal cancer- survival rate- meta-analysis- Iran

Asian Pac J Cancer Prev, 20 (1), 13-21

Introduction

Colorectal cancer (CRC) is the third most common cancer after lung and breast cancer and the fourth leading cause of oncological death in the world, with an estimated 1.4 million cases and 700,000 deaths occurring in 2012 (Torre et al., 2015; Zare-Bandamiri et al., 2017). The incidence of this cancer varies in the world. Nearly, 55% of these cases have occurred in highly developed countries, with the highest rates in Australia and New Zealand, and the lowest in the countries of West Africa (Ferlay et al., 2015).

CRC is one of the most common cancers in Iran, which has increased in recent years. The incidence of this cancer in Iran is lower than other developed countries; however, in recent decades, this rate has increased significantly. According to national reports of Iran cancer registration in 2009, colorectal cancer is the third most common cancer in women and the fourth most common cancer in men (Kumar et al., 2010).

The survival rate is one of the main indicators for evaluating the effect of healthcare, disease control, and measuring the effect of treatment. Survival rates are defined as the proportion of people with the same type and stage of cancer that is living in a specific period of time after the diagnosis(team, 2017). There is a wide geographical distribution in the survival rates of patients with colorectal cancer. The 5-year survival rate varies from 65% in the USA (team, 2017) to 64% in Korea and less than 8% in the countries of sub-Saharan Africa like Gambia and Uganda (Sankaranarayanan et al., 2011). Also, the 5-year survival rate of colorectal cancer in Iran varies from 27% to 85% (Mehrabani et al., 2012; Payandeh et al., 2016b).

Different prognostic factors can influence the survival rates of CRC like age, gender, race, histology type, tumor grade, tumor size, tumor stage, regional lymph nodes metastasis, pathologic stage, and location of
tumor (Park et al., 1999; Moghimi-Dehkordi et al., 2008; Moghimi-Dehkordi et al., 2009; Ghazali et al., 2010). One of the most important factors that affect the survival rate in a patient with colorectal cancer is gender. The result of different studies indicated that the 5-year survival rate in women was significantly better than men (Wichmann et al., 2001; Koo and Leong, 2010; Majek et al., 2013). Another important prognostic factor is the location of the tumor. A different study indicated that the survival rate in rectum cancer was better than the colon ones and it is also depending on the stage of diagnosis (Meguid et al., 2008; Hemminki et al., 2010; Lee et al., 2013; Phipps et al., 2013).

Several studies had conducted to estimate the survival rate of colorectal cancer in Iran. But due to the differences between the results of previous studies, there is no consensus on the survival of colorectal cancer in Iran. Therefore, the aim of this study was to summarize the pooled survival rate of colorectal cancer in Iran.

Materials and Methods

We followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) to perform and report this study (Moher et al., 2009).

Data source and search strategy

In this systematic review and meta-analysis, two reviewers independently searched an international database such as PubMed/Medline, Web of Science (ISI), Scopus, ProQuest, Science Direct, Embase and Google Scholar, and Iranian databases such as MagIran, IranMedex, and Scientific Information Databank (SID) up to December 1st 2017. We conducted initial search strategy using MeSH terms like “Colorectal Neoplasms” AND “Survival Rate”, set of proper keywords, including “Survival” OR “survive” OR “Prognosis”, “Colorectal cancer” OR “Colon cancer” OR “Rectum cancer”, and “Iran”. Finally, we checked the reference list of all included studies, to avoid missing any relevant articles. No limitations in terms of language and date of publications were considered in this study. The EndNote software (version X7, for Windows, Thomson Reuters, Philadelphia, PA, USA) was used to facilitate screening the result of the systematic search.

Study selection

All cohort studies that reported the survival rate or survival time and longevity of patient diagnosed with colorectal cancer among an Iranian population, without any limitation up to December 1st, 2017 were included in this study. Studies that discussed colorectal cancer but they did not report the survival rate or they had insufficient information were excluded from the study. The conference proceedings, letters, review and meta-analysis, cross-sectional, case report, and case series studies were also excluded. The two authors (KH, M, and E, SH) independently reviewed the search result by title, abstract and full text and disagreement between two authors were resolved by discussion or with a third author (M, KH). The details of the screening process and the study inclusion are shown in Figure 1.

Quality assessment and data extraction

In order to assess the risk of bias in all full-text articles included in this study, we used the recommended STROBE checklist (Von Elm et al., 2014) as follows: (a) clearly defined the source of participant selection, (b) clearly defined the eligibility criteria, (c) explain how to measure the exposure, (d) explain how to measure the outcome, (e) give the follow up information, (d) explain about sample size and power of the study. The quality of the included studies was assessed independently by two authors (KH, M, and E, SH). The studies were classified in three categories by using this checklist, which includes: low quality if each study obtained 30-59% of the total score, intermediate quality if each study retrieved 60-79% of the total score, and more than 70% considered as high quality. The value of weighted kappa statistic between author agreements was 86%. After confirming the quality of each study, two authors (KH, M, and E, SH) were independently extracted the data to the pre-specified data extraction sheet in Microsoft Excel. Variables extracted from each eligible study included: first author name, year of publication, period of study, location of study, study design, median follow up time, source of data, type of statistical analysis, sample size, mean age, the survival rate of one, three and five years with standard error or 95% confidence interval (CI).

Statistical analysis

We generated 1, 3 and 5 year pooled survival rate by using Der-Simonies and Laird’s random-effect models. To calculate the standard error of survival rate and its variance, the 1 to 5-year survival rate in each study was considered as a binomial distribution. To graphically display the combined estimate of one, three and five-year survival rate, we used the metaprop command in Stata 11. The metaprop command was specific to binomial data and for proportions near boundaries (i.e., in this instance 100% at 1-year survival or zero at stage IV) which allows computation of exact binomial and score test-based confidence intervals by allowing Freeman-Tukey double arcsine transformation to stabilize the variances. We used a Chi-squared test at the 5% significance level (p < 0.05) and I² index to determine the statistical heterogeneity between studies. To find the potential source of heterogeneity we used meta-regression model with a suspected variable such as; sample size, publication year and location of study. Furthermore, we used subgroup analysis by gender, tumor site, and location of a study to determine the source of heterogeneity. Sensitivity analysis was done to investigate the effect of each study on the pooled 1, 3 and 5-year survival rate. In this study, the publication bias was not assessed because the probability of survival is always a positive number between zero and one and therefore, if we saw asymmetry in funnel plots it is due to the distribution of all studies on the right side of the vertical line that which is not related to publication bias.

We used Microsoft Excel 2010 to preparing data extraction sheet. Also, we used Stata11 (StataCorp, College Station, TX, USA) to conducted meta-analysis.
Results

Description of study

After initial search and screening by title, abstract and full text, 38 studies were enrolled according to the eligibility criteria which contain 19,160 patients, of the 61% were male (Figure 1, Table 1, 2, 3). From the total sample size of included studies, 10309 (53.8%) patient were from Tehran, 1,527 (7.96%) patient were from the south, 1,291 (6.73%) subjects from the west, 859 (4.48%) patients from center and 413 (2.15%) and 227 (1.18%) patients were from the east and the north, respectively. We have two national studies that comprised 4,534 (23.66%) subjects from the whole country. The mean age of the patients with colorectal cancer included in this study was 53.1 years.

Survival rate

Using the random effect model, the pooled 1, 3 and 5 year survival rate of patient with colorectal cancer were calculated 0.84 (95% CI: 0.81-0.87), 0.64 (95% CI: 0.59-0.70), and 0.54 (95% CI:0.49-0.58), respectively. The heterogeneity index (I²) for 1, 3 and 5 year survival rate was 95.05%, 96.6% and 96.6%, respectively, that revealed the high heterogeneity between studies. To reduce the high heterogeneity between studies we performed subgroup analysis. According to the subgroup analysis, the pooled 1, 3 and 5 year survival rate in male subgroup, were 0.83 (95%CI: 0.79-0.88), 0.55 (95%CI: 0.53-0.57) and 0.44 (95%CI: 0.40-0.48), respectively. In female subgroup, the pooled 1, 3 and 5 year survival rate were 0.84 (95%CI: 0.80-0.88), 0.57 (95%CI: 0.52-0.63) and 0.50 (95%CI: 0.44-0.56), respectively. Furthermore, the result of subgroup analysis based on the tumor site revealed that, the pooled 1, 3 and 5 year survival rate in colon cancer subgroup were 0.90 (95%CI:0.87-0.93), 0.69 (95%CI: 0.63-0.75) and 0.60 (95%CI: 0.49-0.70) respectively. In rectum cancer subgroup the pooled 1, 3 and 5 year survival rate were 0.88 (95%CI: 0.81-0.95), 0.73 (95%CI: 0.62-0.83) and 0.54 (95%CI: 0.36-0.69), respectively.

| Table1. Characteristics of Included Studies in Meta-Analysis (Colorectal Cancer) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| NO | First Author | Year of Publication | Year of study | Location | No. of patients | Mean age ± SD | Survival rate (%) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Abbasi Asl M et al (2015) | 2015 | 2007-2009 | Tehran | 88 | 56±13.91 | 79.2 63.7 52.5 46.2 39.6 |
| 2 | Abdollahian Z et al (2016) | 2016 | 1987-2012 | Tehran | 232 | 18-82 | 90 72 64 |
| 3 | Allahyarri A et al (2016) | 2016 | 2009-2015 | Mashhad | 96 | 57.8 | 76 |
| 4 | Ansari R et al (2007) | 2007 | 1995-2003 | Tehran | 237 | 58.1±14.8 | 80 49 |
| 5 | Dianatinasab M (2016) | 2016 | 2009-2014 | Shiraz | 220 | 95 87 51 |
| 6 | Esma-Ashari F et al (2008) | 2008 | 2000-2004 | Iran | 2342 | 58.1±14.7 | 79.2 65 57.3 51.7 47.3 |
| 7 | Faghihzade S et al (1998) | 1998 | 1986-1990 | Tehran | 216 | 86 64 51.6 48.9 40.6 |
| 8 | Fatemi R et al (2015) | 2015 | 2004-2013 | Tehran | 107 | 53.5±12.6 | 73.8 |
| 9 | Hashemian A.H et al (2017) | 2017 | 2001-2007 | Tehran | 1127 | 91.2 73.2 61 |
| 10 | Madadizadeh F et al (2017) | 2017 | 2005-2010 | Fars | 561 | 55.7±13.6 | 59.6 |
| 11 | Mehrbani D et al (2012) | 2012 | 2003-2008 | Shiraz | 243 | 58.6±13.5 | 53.9 50.3 27.02 |
| 12 | Mehrkhani F et al (2009) | 2008 | 1999-2002 | Tehran | 1090 | 50.5±5.1 | 72 54 47 |
| 13 | Moghimi-Dehkordi B et al (2008) | 2008 | 2002-2007 | Tehran | 1127 | 53.5±14.3 | 61 47.9 |
| 14 | Moradi A et al (2009) | 2009 | 2000-2005 | Iran | 2192 | 57.8±14.9 | 84 68 54 43 41 |
| 15 | Nasiri Sh et al (2010) | 2010 | 1999-2002 | Tehran | 109 | 50.5±16.1 | 72 54 47 |
| 16 | Omidvari sh et al (2013) | 2013 | 2004-2010 | Shiraz | 153 | 57.15 | 69.4 |
| 17 | Parsaei R et al (2015) | 2015 | 2006-2011 | Mashhad | 241 | 56.6±0.9 | 81 66 53 44 |
| 18 | Payandeh M et al (Payandeh et al., 2016a) | 2016 | 2002-2014 | Kermanshah | 183 | 54.2±13.2 | 84.6 |
| 19 | Rahimi/Pordanjani S (Chahmatki et al., 2016) | 2016 | 2000-2010 | Chaharmahal and Bakhtiari | 452 | 59.1±19.9 | 71.9 52.5 |
| 20 | Rasouli M.A et al (2017) | 2017 | 2009-2014 | Kurdistan | 335 | 60.5±1.12 | 87 69 57 42 33 |
| 21 | Rosheanai G et al (2014) | 2014 | 2005-2013 | Hamadan | 169 | 56.4±14.5 | 89 54 31 |
| 22 | Saeedi Saeidi H et al (2009) | 2009 | 2001-2006 | Mashhad | 76 | 50 | 68.2 |
| 23 | Safaei A et al (2012) | 2012 | 2002-2007 | Tehran | 1127 | 53 | 61 |
| 24 | Saki Malehi A et al (2012) | 2012 | 2000-2007 | Tehran | 739 | 59.7±12.85 | 63.3 |
| 25 | Semmani S et al (2016) | 2015 | 2006-2007 | Golestan | 227 | 54 71 52 44 |
| 26 | Vakili M et al (2014) | 2014 | 2001-2011 | Yazd | 604 | 58.9±19.9 | 72.2 |
| 27 | Zare-Bandamiri M et al (2016) | 2016 | 2005-2010 | Shiraz | 570 | 55.8±23.6 | 56.9 |
| 28 | Zaargar A et al (2016) | 2016 | 2007-2009 | Qazvin | 35 | 64.7±13.2 | 75 |
| 29 | Safae A (2010) | 2010 | 2002-2005 | Tehran | 110 | 50.1 92.6 80.1 41.3 |
**Meta-regression analysis**

To identify the effect of the potential variable like the year of study, sample size and location of study as a source of heterogeneity, we used meta-regression analysis (Table 4). In the univariable model there was no significant association between included variables and pooled 1, 3 and 5-year survival rate (p-value>0.05). In multivariable meta-regression model, only there was a significant association between year of study and pooled 5-year survival ($\beta= 18.9$, $P=0.01$).

**Sensitivity analysis**

According to the result of sensitivity analysis that indicated in Table 5, after omitting each study there were no significant changes in the pooled 1, 3, and 5-year survival rate of the patients with CRC.

---

**Table 2. Characteristics of Included Studies in Meta-Analysis (Colon and Rectum Cancer)**

| NO | First Author          | Year of Publication | Year of study | Location | Mean age ± SD | Tumor site | No. of patients | Survival rate (%) |
|----|-----------------------|---------------------|---------------|----------|---------------|------------|----------------|------------------|
| 1  | Akhavan A et al (2014)| 2014                | 2004-2012     | Yazd     | Colon         | Rectum     | 119            | 97 88 55         |
| 2  | Akhoond M et al (2010)| 2010                | 2002-2007     | Tehran   | 53.5±14.3     | Colon      | 802            | 88.7 77.9 68.5 61.4 56.8 |
| 3  | Amirifard N et al (2016)| 2016              | 2012-2015     | Kermanshah | 57.6±12.5     | Colon      | 25             | 71               |
| 4  | Amirifard N et al (2016)| 2016              | 2011-2016     | Kermanshah | 52.8±14.5     | Colon      | 102            | 76               |
| 5  | Asghari-Jafarabadi M et al (2009) | 2009       | 2002-2007 | Tehran | 55±37.6       | Colon      | 802            | 91.7 83.7 75.9 69 63.3 |
| 6  | Fatemi R et al (2015) | 2015                | 2004-2013     | Tehran   | 53.5±12.6     | Colon      | NR             | 75.9               |
| 7  | Gohari M et al (2011) | 2011                | 2002-2007     | Tehran   | 53.7±14.6     | Colon      | 790            | 92 71 48               |
| 8  | Heidarnia M.A et al (2013) | 2013           | 2005-2006     | Tehran   | 63±11.8       | Colon      | 580            | 86 71 42               |
| 9  | Sanei B et al (Sanei et al., 2013) | 2013         | 2003-2012     | Isfahan  | 58.9±13.8     | Colon      | 101            | 63.6               |

---

**Figure 1. Flowchart of Search and Studies Selection**
Discussion

In this meta-analysis, we estimated the pooled 1, 3, and 5 year survival rates of patients with colorectal cancer in Iran. The pooled 1, and 3 year survival rates in our study were 0.84 (95% CI: 0.81-0.87) and 0.64 (95% CI: 0.59-0.70), respectively. In a study conducted in India in 2001, the 1 and 3 year survival rates were 63.4 and 42.2, respectively (Yeole et al., 2001), that was lower than the results of our study. Otherwise, in a study by Coleman in 2011 the 1-year survival rate in Australia, Canada, Denmark, Norway, Sweden, and the UK was reported by 84.9, 83.5, 77.7, 82.4, 83.8, and 74.7, respectively (Coleman et al., 2011). The result of this study is consistent with the finding of our study. In a study from China in 2013, the 3-year survival rate was reported 0.74 (Yuan et al., 2013). The 5-year survival rate in our study was 0.54 (0.49-0.58).

Table 3. Result of Subgroup Analysis for Estimating the Pooled 1, 3, and 5 Year Survival Rate in Patient with Colorectal Cancer

| NO | Title | Subgroup | No. of study | 1 year survival 95%CI | No. of study | 3 year survival 95%CI | No. of study | 5 year survival 95%CI |
|----|-------|----------|--------------|------------------------|--------------|------------------------|--------------|------------------------|
| 1  | Tumor site | Colorectal | 19 | 0.84 (0.81-0.87) | 18 | 0.64 (0.59-0.70) | 26 | 0.54 (0.49-0.58) |
|    |        | Colon | 4 | 0.90 (0.87-0.93) | 4 | 0.69 (0.63-0.75) | 5 | 0.60 (0.49-0.70) |
|    |        | Rectum | 6 | 0.88 (0.81-0.95) | 6 | 0.73 (0.62-0.83) | 6 | 0.54 (0.36-0.69) |
| 2  | Gender | Male | 6 | 0.83 (0.79-0.88) | 3 | 0.55 (0.53-0.57) | 7 | 0.44 (0.40-0.48) |
|    |        | Female | 6 | 0.84 (0.80-0.88) | 3 | 0.57 (0.52-0.63) | 7 | 0.50 (0.44-0.56) |

Table 4. Meta-Regression Analysis for Assessing the Effect of Suspected Variables on the Pooled 1, 3, 5 and 10 Year's Survival

| Survival rate | Variable | β     | SE  | P-value | β     | SE  | P-value |
|---------------|----------|-------|-----|---------|-------|-----|---------|
| 1 year survival rate | Year of study | -0.29 | 4.4  | 0.94   | 0.41  | 6.2 | 0.9    |
|               | Sample size | 1.5   | 4.07 | 0.7    | 0.93  | 5   | 0.8    |
|               | Location   | -1.1  | 3.9  | 0.7    | -0.95 | 5   | 0.8    |
| 3 year survival rate | Year of study | 3.6   | 6.9  | 0.6    | 7.3  | 7.6 | 0.3    |
|               | Sample size | 3.3   | 6.1  | 0.5    | 2.8  | 6.6 | 0.6    |
|               | Location   | -9.5  | 5.5  | 0.1    | -10.7 | 6   | 0.09   |
| 5 year survival rate | Year of study | 9.7   | 6    | 0.1    | 18.9 | 7.1 | 0.01   |
|               | Sample size | -0.88 | 7    | 0.9    | 7.4  | 7.05 | 0.3    |
|               | Location   | -3    | 6    | 0.6    | -11  | 6.2 | 0.09   |

Figuer 2. Forest Plot of Pooled 1 Year Survival Rate in Patient with Colorectal Cancer
was 0.54 (95% CI: 0.49-0.58). In studies that conducted in developing countries like India in 2001 (Yeole et al., 2001) and in Malaysia in 2010 (Ghazali et al., 2010), the 5-year survival rate was reported 33.6 and 34.3 respectively.

In a study from Japan in 2005, the 5-year survival rate was reported 61.4 (Shiono et al., 2005). Also, studies that conducted in Germany in 2012, USA, England, France, and Italy were reported the 5-year survival rate 65, 65, 52.7, 60.3 and 59.3 respectively (Brenner et al., 2012; Majek et al., 2012; team, 2017). And also in a study conducted in China, the 5-year survival rate was reported 0.68 (Yuan et al., 2013).

The 5-year survival rate of patients with colorectal cancer in our country is lower than the developed regions. Therefore, we conclude that the survival rate of patients with colorectal cancer in Iran is between developed and developing countries.

The survival rate of CRC patient in Iran like other...
Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis

DOI:10.31557/APJCP.2019.20.1.13

Asian Pacific Journal of Cancer Prevention, Vol 20

patients in the world depends on various factors such as demographic, pathologic and tumor characteristics, geographical distribution and gene mutation or having a family history (Dolatkhah et al., 2015; Rafiemanesh et al., 2016). But the most important factor for Iranian CRC patient is that they disease diagnosed in advanced stage (Aryaei et al., 2013; Dolatkhah et al., 2015). So this significant difference in 5-year survival rate may be due to, poorly established screening program like the fecal occult blood test, sigmoidoscopy and colonoscopy and limited accessibility in developing region (Sankaranarayanan et al., 2011).

According to the high heterogeneity between the results of the included studies, we used subgroup analysis. The results of meta-analysis in subgroup based on the tumor site revealed that the pooled 1 and 5 year survival rate in colon cancer was better than the rectum cancer and only 3-year survival rate was better in rectum cancer than the colon cancer.

In a study from Malaysia in 2010, the 5-year survival rate in colon cancer was reported 0.44 and 0.23 for rectum cancer (Ghazali et al., 2010). In China, in 1992-1995 the 5-year survival rate in Colon and rectum cancer was reported at 0.43 and 0.41 respectively (Xiang et al., 2011). The result of these studies was similar to the results of our study.

The result of studies in USA (team, 2017) and England (Morris et al., 2011) revealed that the 5-year survival rate is slightly higher for rectal cancer than colon cancer.

The result of some studies suggest that, the different site of tumors in colorectal cancer have been influenced by different risk factors and may have different biological and molecular profile, that they can results in differences in survival rate (Andrieu et al., 2004; Mahipal et al., 2006; Kim et al., 2007; Yamauchi et al., 2012; Phipps et al., 2013). In one study the differences between survival rates by tumor site were dependent on stage at diagnosis, for example, there were no differences in survival of colon and rectum cancer in early stage, but in the advanced stage, patient with rectum cancer have better survival than colon cancer (Lee et al., 2013). Other studies claimed that colon cancer has a better response to antitumor drugs than the rectum cancer (Ueo et al., 1991; Lee et al., 2013) and patient with colon cancer has better prognosis than rectum cancer (Li et al., 2007; Lee et al., 2013).

The results of subgroup analysis based on gender indicate that, for all 1, 3, and 5 years, the survival rates for women were better than men.

In a study in Germany in 2013 (Majek et al., 2013) and Cuba in 1994-1995 (Garrote et al., 2011) the age-specific 5-year survival rate in women was better than men that were similar to the result of our study.

The reason for better survival in women than men may be due to higher participation rate in women compared in men for screening programs like fecal occult blood test and colonoscopy (Stock et al., 2011; Pox et al., 2012; Majek et al., 2013). The most important factor for better survival in women is female gonadal hormones that have a protective effect and influence on the immune system. On the other hand, testosterone has a destructive effect on the immunological response (Parkin et al., 2005; Santarelli et al., 2008; Haggar and Boushey, 2009).

Limitation

One of the most important factors that influence the survival of patients with colorectal cancer was the stage of diagnosis. The 5-year survival rate was ranged from 90% in localized stage, 70% for regional and 10% for the patients diagnosed at distant metastatic stage (7:11,17). In our study because of the limited number of conducted study in this filed and using different criteria for staging we can’t estimate the pooled survival rate of the colorectal cancer patient in a different stage.

A large number of studies were excluded due to the overlap of these studies by location and year of the study. Another limitation was that most of the studies were conducted in Tehran and we didn’t have sufficient data for other parts of the country. Also, some studies were reported the survival rate differently, for example, they reported only mean and median survival.

In conclusion, the result of this study indicates that the 1 and 3 year survival rate of the patients with colorectal cancer in Iran was similar to developed countries and 5-year survival rate in our country was between developed and developing countries. The survival of colorectal cancer in all year in women was significantly better than man and the survival rate by tumor site was better in colon cancer than rectum cancer.

References

Abbasi Asl M, Barfæie F, Gohari M, et al (2015). Survival analysis of colorectal cancer patients and its prognostic factors using cox regression. Razi J Med Sci, 22, 21–8.

Abdolalian Z, Rafeie M, Baghestani A, et al (2016). Analyzing the survival of colorectal cancer patients of Tehran Taleghani Hospital using non-mixture cure model. Arak Med Univ J (AMUJ), 19, 98-106.

Akhavan A, Binesh F, Soltani A (2014). Survival of rectal cancer in Yazd, Iran. Asian Pac J Cancer Prev, 15, 4857-60.

Akhoond MR, Kazemnejad A, Hajizadeh E, et al (2010). Comparison of colon and rectum cancer: survival and prognostic factors. Gastroenterol Hepatol Bed Bench, 3, 177-86.

Allahyari A, Ataei-Azimi S, Nazemian F, et al (2016). Clinico pathology figures and survival in the patients with colorectal cancer in Northeast Iran: a review on the literature of Iran. Sch J App Med Sci, 4, 565-8.

Amirifar F, Farshchian N, Choubasz M, et al (2016). Comparison of the overall survival in colon and rectum tumors in Kermanshah province. Sch J App Med Sci, 4, 687-90.

Andrieu N, Launoy G, Guillois R, et al (2004). Estimation of the familial relative risk of cancer by site from a French population based family study on colorectal cancer (CCREF study). Gut, 53, 1322-8.

Ansari R, Amjadi H, Norozbeigi H, et al (2007). Survival analysis of colorectal cancer in patients underwent surgical operation in Shariati and Mehr Hospital-Tehran, in a retrospective study. Govaresh, 12, 7-15.

Aryaei M, Roshandel G, Semnani S, et al (2013). Predictors of colorectal cancer survival in Golestan, Iran: a population-based study. Epidemiol Health, 35, 1-6.

Asghari-Jafariabadi M, Hajizadeh E, Kazemnejad A, et al (2009). Site-specific evaluation of prognostic factors on survival in colon and rectal cancer. Asia Oceania J Cancer Prevention, Vol 10, No 3, 319-324.
Iranian colorectal cancer patients: a competing risks survival analysis. *Asian Pac J Cancer Prev*, **10**, 815-21.

Brenner H, Bouvier AM, Foschi R, et al (2012). Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. *Int J Cancer*, **131**, 1649-58.

Chalmatsi F, Ansari M, Rahimi S, et al (2016). Survival rate of patients with colorectal cancer in Charmahal and Bakhtiari Province, Iran. 2000-2010. *Armaghan Danesh*, **20**, 1086-95.

Coleman M, Forman D, Bryant H, et al (2011). Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet*, **377**, 127-38.

Dianatinasab M, Ghaem H, Rezaianzadeh A, et al (2016). Colorectal Cancer Mortality in Shiraz, Iran. *Asian Pac J Cancer Prev*, **17**, 4101-5.

Dolatkhah R, Somi MH, Bonyadi MJ, et al (2015). Colorectal cancer in Iran: molecular epidemiology and screening strategies. *J Cancer Epidemiol*, **2015**, 1-10.

Esna-ashari F, Sohrabi M, Abadi A, et al (2008). Colorectal cancer prevalence according to survival data in Iran in 2007 *Res Med*, **32**, 221-5.

Faghihzade S, Ghareaghagi Asl R, Mohammadi E (1998). Determine the survival and hazard function in patient with colorectal cancer Modarres, [in persian]. *MAMS*, **1**, 53-6.

Fatemi SR, Pourhoseingholi MA, Asadi F, et al (2015). Recurrence and five-year survival in colorectal cancer patients after surgery. *Iran J Cancer Prev*, **8**, 1-6.

Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence, mortality, survival, and risk factors. *Int J Cancer*, **136**, 359-86.

Garrote L, Alvarez Y, Babie P, et al (2011). Cancer survival in Cuba, 1994-1995. *IARC Sci Publ*, **162**, 89-95.

Ghazali AK, Musa KI, Naing NN, et al (2010). Prognostic factors in patients with colorectal cancer at Hospital Universiti Sains Malaysia. *Asian J Surg*, **33**, 127-33.

Gohari MR, Biglarian A, Bakhshi E, et al (2011). Use of an artificial neural network to determine prognostic factors in colorectal cancer patients. *Asian Pac J Cancer Prev*, **12**, 1469-72.

Haggar FA, Boushey RP (2009). Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colorectal Surg*, **22**, 191-7.

Hashemian A, Garshashi M, Pourhoseingholi M, et al (2017). A comparative study of cox regression vs. log-logistic regression (with and without its frailty) in evaluating survival time of patients with colorectal cancer. *J Med Biomed Sci*, **6**, 35-43.

Heidarmia MA, Monfared ED, Akbari ME, et al (2013). Social determinants of health and 5-year survival of colorectal cancer. *Asian Pac J Cancer Prev*, **14**, 5111-6.

Hemminki K, Santi I, Weires M, et al (2010). Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. *BMC Cancer*, **10**, 688.

Kim GP, Colangelo LH, Wieand HS, et al (2007). Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study. *J Clin Oncol*, **25**, 767-72.

Koo JH, Leong RW (2010). Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer. *J Gastroenterol Hepatol*, **25**, 33-42.

Kumar S, Burney IA, Al-Ajmi A, et al (2010). Changing trends of breast cancer survival in sultanate of oman. *J Oncol*, **2011**, 1-7.

Lee Y-C, Lee Y-L, Chuang J-P, et al (2013). Differences in survival between colon and rectal cancer from SEER data. *PLoS One*, **8**, e78709.

Li M, Li J, Zhao A, et al (2007). Colorectal cancer or colon and rectal cancer?. *Oncology*, **73**, 52-7.

Madadizadeh F, Ghanbarnejad A, Ghavami V, et al (2017). Applying additive hazards models for analyzing survival in patients with colorectal cancer in Fars province, Southern Iran. *Asian Pac J Cancer Prev*, **18**, 1077.

Mahipal A, Anderson KE, Limburg PJ, et al (2006). Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women’s health study. *Cancer Epidemiol Prev Biomarkers*, **15**, 1785-90.

Majek O, Gondos A, Jansen L, et al (2012). Survival from colorectal cancer in Germany in the early 21st century. *Br J Cancer*, **106**, 1875-80.

Majek O, Gondos A, Jansen L, et al (2013). Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. *PLoS One*, **8**, e68077.

Meguid RA, Slidell MB, Wolfgang CL, et al (2008). Is there a difference in survival between right-versus left-sided colon cancers?. *Ann Surg Oncol*, **15**, 2388.

Mehrabani D, Almasi-Hashiani A, Moshfeghi K, et al (2012). Survival rate and its predictors in colorectal cancer patients, Southern Iran. *Middle East J Sci Res*, **12**, 1072-7.

Mehrkhani F, Nasiri R, Donboli K, et al (2009). Prognostic factors in survival of colorectal cancer patients after surgery. *Colorectal Dis*, **11**, 157-61.

Mohgimi-Dehkordi B, Safaee A, Zali MR (2008). Prognostic factors in 1,138 Iranian colorectal cancer patients. *Int J Colorectal Dis*, **23**, 683-8.

Mohgimi-Dehkordi B, Safaee A, Zali MR (2009). Comparison of colorectal and gastric cancer: survival and prognostic factors. *Saud J Gastroenterol*, **15**, 18.

Moher D, Liberati A, Tetzlaff J, et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*, **6**, e1000097.

Moradi A, Khayamzadeh M, Guya MM, et al (2009). Survival of colorectal cancer in Iran. *Asian Pac J Cancer Prev*, **10**, 583-6.

Morris EJ, Sandin F, Lambert PC, et al (2011). A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004. *Gut*, **60**, 1087-93.

Nasiri S, Sorush A, Karamnezhad M, et al (2010). Prognostic factors in the survival rate of colorectal cancer patients after surgery. *Iran J Surg*, **18**, 50-6 [In persian].

Omidvari S, Hamedi SH, Mohammadianpanah M, et al (2013). Comparison of abdominoperineal resection and low anterior resection in lower and middle rectal cancer. *J Egypt Natl Canc Inst*, **25**, 151-60.

Park YJ, Park KJ, Park J-G, et al (1999). Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. *World J Surg*, **23**, 721-6.

Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. *CA Cancer J Clin*, **55**, 74-108.

Parsae R, Fekri N, Shahid S, et al (2015). Prognostic factors in the survival rate of colorectal cancer patients. *North Khorasan Univ Med Sci*, **7**, 45-53 [In Persian].

Payandeh M, Sadeghi M, Ghorbani S, et al (2016a). The survival and KRAS/BRAF testing in colorectal cancer: a review on the literature of Iran. *Sch J App Med Sci*, **4**, 1447-52.

Payandeh M, Sadeghi M, Ghorbani S, et al (2016b). The survival and KRAS/BRAF testing in colorectal cancer: a review on the literature of Iran. *SJAMS*, **4**, 1447-52.
Phipps AI, Lindor NM, Jenkins MA, et al (2013). Colon and rectal cancer survival by tumor location and microsatellite instability: the colon cancer family registry. *Dis Colon Rectum*, **56**, 937.

Pox CP, Altenhofen L, Brenner H, et al (2012). Efficacy of a nationwide screening colonoscopy program for colorectal cancer. *Gastroenterology*, **142**, 1460-7.e2.

Rafieimanesh H, Pakzad R, Abedi M, et al (2016). Colorectal cancer in Iran: Epidemiology and morphology trends. *EXCLI J*, **15**, 738.

Rasouli MA, Moradi G, Roshani D, et al (2017). Prognostic factors and survival of colorectal cancer in Kurdistan province, Iran: A population-based study (2009–2014). *Medicine*, **96**, 1-7.

Roshanaci G, Komijani A, Sadighi A, et al (2014). Prediction of survival in patients with colorectal cancer referred to the Hamadan MRI center using of Weibull parameter model and determination of its risk factors during 2005-2013. *AMUJ*, **16**, 1-11.

Saedi Saed H, Ghavannasiri M, Sailanian Toosi M, et al (2009). The assessment of prognostic factors in patients with nonmetastatic rectal Adenocarcinoma referred to Omid Hospital ( Mashhad), Iran. *J Gorgan Univ Med Sci*, **11**, 28-32 [InPersian].

Safaei A, Moghimi-Dehkordi B, Fatemi S, et al (2010). Characteristics of colorectal mucinous adenocarcinoma in Iran. *Asian Pac J Cancer Prev*, **11**, 1373-5.

Safaei A, Moghimi-dehkordi B, Fatemi S, et al (2012). Pathology and prognosis of colorectal cancer. *Iran J Cancer Prev*, **2**, 137-41.

Saki Malehi A, Hajizadeh E, Fatemi R (2012). Evaluation of prognostic variables for classifying the survival in colorectal patients using the decision tree. *Iran J Epidemiol*, **8**, 13-9.

Saniei B, Mahmoudieh M, Kolahdouzan M, et al (2013). Survival time and recurrent rate in patients with rectum cancer. *J Isfahan Med Sch*, **31**, 1194-207.

Sankaranarayanan R, Swaminathan R, Jayant K, et al (2011). An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. *IARC Sci Publ*, **162**, 257-91.

Santarelli RL, Pierre F, Corpet DE (2008). Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence. *Nutr Cancer*, **60**, 131-44.

Semnani S, Noorafkan Z, Aryanie M, et al (2016). Determinants of healthcare utilisation and predictors of outcome in colorectal cancer patients from Northern Iran. *Eur J Cancer Care*, **25**, 318-23.

Shinno S, Ishii G, Nagai K, et al (2005). Histopathologic prognostic factors in resected colorectal lung metastases. *Ann Thorac Med*, **79**, 278-82.

Stock C, Ihle P, Schubert I, et al (2011). Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. *Endoscopy*, **43**, 771-81.

team TACSmacc (2017). Colorectal Cancer Facts and Figures [Online]. Available: https://www.cancer.org/cancer/colorectal-cancer/detection-diagnosis-staging/survival-rates.html.

Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. *CA Cancer J Clin*, **65**, 87-108.

Ueo H, Maehara Y, Saito A, et al (1991). Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. *Oncology*, **48**, 158-61.

Vakili M, Aghakoochak A, Pirdehghan A, et al (2014). The survival rate of patients with colorectal cancer in Yazd during 2001-2011. *SSU-J*, **22**, 1187-95.

Von Elm E, Altman DG, Egger M, et al (2014). The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Int J Surg*, **12**, 1495-9.

Wichmann M, Müller C, Hornung H, et al (2001). Gender differences in long-term survival of patients with colorectal cancer. *Br J Surg*, **88**, 1092-8.

Xiang Y, Jin F, Gao Y (2011). Cancer survival in Shanghai, China, 1992-1995. In Eds IARC Press, pp 55-68.

Yamauchi M, Morikawa T, Kuchiba A, et al (2012). Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut*, gutjnl-2011-300865.

Yeole B, Sunny L, Swaminathan R, et al (2001). Population-based survival from colorectal cancer in Mumbai,( Bombay) India. *Eur J Cancer*, **37**, 1402-8.

Yuan Y, Li M-D, Hu H-G, et al (2013). Prognostic and survival analysis of 837 Chinese colorectal cancer patients. *World J Gastroenterol*, **19**, 2650.

Zare-Bandamiri M, Fararouei M, Zohouriinia S, et al (2017). Risk factors predicting colorectal cancer recurrence following initial treatment: A 5-year cohort study. *Asian Pac J Cancer Prev*, **18**, 2465.

Zare-Bandamiri M, Khanjani N, Jahani Y, et al (2016). Factors affecting survival in patients with colorectal cancer in Shiraz, Iran. *Asian Pac J Cancer Prev*, **17**, 159-63.

Zargar A, Miroliae A, Gooraji SA, et al (2016). Determination of effective factors on survival of GI cancers: Results of five years follow up in Iranian population. *Glob J Health Sci*, **8**, 256.